The global COVID-19 pandemic caused by the novel SARS-CoV-2 coronavirus created an urgent need for protective interventions. Fortunately, new advances in vaccine development — including nucleic acid-based approaches — have enabled the unprecedented rollout of multiple vaccine products within a year from the onset of the pandemic.
However, SARS-CoV-2 continues to evolve, and new viral variants harboring mutations appear to enable escape from antibody neutralization. Multiple approaches will likely be required to combat these threats as the scientific and pharmaceutical communities continue to develop anti-SARS-CoV-2 therapeutics and vaccines.
The ability to rapidly accelerate the design-build-test-cycle of vaccine development is critical for addressing pandemic disease outbreaks. Synthetic RNA vaccine platforms, pioneered during the COVID-19 pandemic, allow for rapid, scalable, and cell-free manufacturing of therapeutic candidates. Because time is of the essence when combating emerging SARS-CoV-2 variants, having the right technology in place to develop and scale vaccine development is critical.
In our next webinar led by Dr. Jesse Erasmus from the University of Washington School of Medicine, Dr. Erasmus discusses the top challenges facing his research efforts to enhance COVID-19 vaccine stability, delivery, and immunogenicity. In the webinar, you will also learn how Dr. Erasmus has overcome these challenges and accelerated his discovery process to develop a two-vialed replicating RNA (repRNA) vaccine.
Date and time:
May 5, 2021
8:00 am PDT